Document:

Exhibit 10.12.1

 

Amendment #1

 

Consulting Agreement dated October 17, 2016 between

ProMIS Neurosciences, Inc. and Danforth Advisors, LLC

 

This Amendment No. 1 to Consulting
Agreement (“Amendment”) is made as of March 27, 2017 (“Effective Date”), by and between ProMIS Neurosciences,
Inc. (“Company”) and Danforth Advisors, LLC (“Consultant” or “Danforth”). Capitalized terms used but
not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Danforth Advisors and the Company
dated as of October 17, 2016 (“Agreement”).

 

WHEREAS, Danforth is
engaged by the Company under the terms and conditions of the Consulting Agreement; and

 

WHEREAS, the Company
and Consultant mutually desire to amend the scope of the Agreement.

 

NOW, THEREFORE, in
consideration of the premises and the mutual covenants and agreements herein contained and for the other good and valuable consideration,
receipt of which is hereby acknowledge, the parties hereby agree as follows:

 

		·	Exhibit A, Description of Services and Schedule of Fees, shall be hereby modified to:

 

		o	Add Kristi Lanier as a VP of Finance Consultant at an hourly rate of $215/hour. The Services to be provided
are more fully described in Exhibit A-1.

 

		o	Replace the Fee Section entirely, as illustrated in Exhibit A-1. Notably, the CFO Services provided by
Daniel Geffken will now be provided under a retainer agreement.

 

		·	Except as specifically provided for in this Amendment, the terms of the Agreement shall be unmodified
and shall remain in full force and effect.

 

This Amendment may be executed in one or more
counterparts, each of which shall be considered an original instrument, but all of which shall be considered one and the same Amendment,
and shall become binding when one or more counterparts have been signed by each of the parties and delivered to the other.

 

IN WITNESS WHEREOF, this Amendment
has been executed by the Company and Danforth Advisors, LLC to be effective as of the date first above written.

 

********

 

    

     

    

 

	
    DANFORTH ADVISORS, LLC 

    

    

    

    
	 	
    PROMIS NEUROSCIENCES, INC. 

    

    

    

    

	 	 	 
	By:	/s/ Gregg Beloff            	 	By:	/s/ Eugene Williams                             
	Print Name: Gregg Beloff	 	Print Name: Eugene Williams
	Title: Managing Director	 	Title: Executive Chairman
	Date: 3/30/17	 	Date: 3/28/17

 

    

     

    

 

EXHIBIT A-1

 

Description of Additional Services

 

[Intentionally Omitted]Exhibit 10.12.2

 

AMENDMENT NO. 2 TO CONSULTING AGREEMENT

 

This Amendment No. 2
to Consulting Agreement (“Amendment No. 2”) is made as of last date of signature below (“Amendment No. 2 Effective
Date”), by and between ProMIS Neurosciences, Inc. with a principal place of business being 1920 Yonge Street, Suite 200,
Toronto, ON M4S 3E2 (“Company”) and Danforth Advisors, LLC, with a principal place of business being 91 Middle Road, Southborough,
MA 01772 (“Danforth”). Capitalized terms use but not defined herein shall have the respective meaning set forth in the Consulting
Agreement by and between Danforth Advisors and the Company dated as of October 17, 2016 (“Agreement”). Collectively,
Danforth and Company may be referred to as “Parties” and either individually as “Party”.

 

WHEREAS,
Danforth is engaged by the Company under the terms and conditions of the Agreement to provide certain Services;

 

WHEREAS,
the Term of the Agreement was set to expire on October 17, 2017; and

 

WHEREAS,
Parties now agree to extend the Term of the Agreement such that it will expire on October 17, 2018 and modify the agreement as further
detailed below.

 

NOW,
THEREFORE, the Agreement is revised to read as follows:

 

		1.	Section 3. Term and Termination The term of this Agreement will commence on the Effective
Date and will continue through October 17, 2018 (the “Term”). This Agreement may be extended for an additional period
by mutual written agreement. This Agreement may be terminated by either Party hereto: (a) with Cause (as defined below), upon thirty
(30) days prior written notice to the other Party; or (b) without cause upon sixty (60) days prior written notice to the other Party.
For purposes of this Section 3, “Cause” shall include: (i) a breach of the terms of this Agreement which is not
cured within thirty (30) days of written notice of such default or (ii) the commission of any act of fraud, embezzlement or deliberate
disregard of a rule or policy of the Company.

 

Except as specifically provided for in this Amendment
No. 2, the terms of the Agreement shall be unmodified and shall remain in full force and effect. For avoidance of doubt this Agreement
remained in effect the entire time between October 17, 2017 and the Effective Date of this Amendment No. 2.

 

This Amendment No. 2 may be executed in one
or more counterparts, each of which shall be considered an original instrument, but all of which shall be considered one and the same
Amendment No. 2, and shall become binding when one or more counterparts have been signed by each of the parties and delivered to
the other.

 

IN WITNESS WHEREOF, this Amendment
No. 2 has been executed by the Company and Danforth to be effective as of Amendment No. 2 Effective Date.

 

********

 

     

     

    

 

	DANFORTH ADVISORS, LLC	 	PROMIS NEUROSCIENCES, INC.
	 	 	 
	/s/ Gregg Beloff	 	/s/ Eugene Williams
	Name 	 	Name
	 	 	 
	Gregg Beloff	 	Eugene Williams
	Print Name	 	Print Name
	 	 	 
	Managing Director	 	Executive Chairman 
	Title	 	Title 
	 	 	 
	12/7/17	 	12/12/17 
	Date	 	Date

 

    2Exhibit 10.12.3

 

Amendment #3

 

Consulting Agreement dated October 17, 2016
between

 

ProMIS Neurosciences, Inc. and Danforth
Advisors, LLC

 

This Amendment No. 3
to Consulting Agreement (“Amendment”) is made as of August 28, 2018 (“Effective Date”), by and between ProMIS
Neurosciences, Inc. (“Company”) and Danforth Advisors, LLC (“Consultant” or “Danforth”). Capitalized
terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Danforth Advisors
and the Company dated as of October 17, 2016 (“Agreement”).

 

WHEREAS, Danforth is
engaged by the Company under the terms and conditions of the Consulting Agreement; and

 

WHEREAS, the Company
and Consultant mutually desire to amend the term and scope of the Agreement.

 

NOW, THEREFORE, in
consideration of the premises and the mutual covenants and agreements herein contained and for the other good and valuable consideration,
receipt of which is hereby acknowledge, the parties hereby agree as follows:

 

		1.	Section 3. Term and Termination is hereby modified to extend the term of the Agreement until
October 17, 2019.

 

		2.	Exhibit A, Description of Services and Schedule of Fees, shall be hereby modified to:

 

		·	Add Lucy Sennett as a Controller Consultant at an hourly rate of $155/hour. The Services to be provided
are more fully described in Exhibit A-3.

 

		3.	Except as specifically provided for in this Amendment, the terms of the Agreement shall be unmodified
and shall remain in full force and effect.

 

This Amendment may be executed in one
or more counterparts, each of which shall be considered an original instrument, but all of which shall be considered one and the same
Amendment, and shall become binding when one or more counterparts have been signed by each of the parties and delivered to the other.

 

IN WITNESS WHEREOF, this Amendment
has been executed by the Company and Danforth Advisors, LLC to be effective as of the date first above written.

 

********

 

     

     

    

 

	DANFORTH ADVISORS, LLC	 	PROMIS NEUROSCIENCES, INC.
	 	 	 
	By: 	/s/ Gregg Beloff	 	By: 	/s/ Eugene Williams
	 	 	 
	Print Name:      Gregg Beloff	 	Print Name:      Eugene Williams
	 	 	 
	Title:   Managing Director	 	Title:   Executive Chairman
	 	 	 
	Date: 	 	 	Date:    8/31/18

 

    2

     

    

 

EXHIBIT A-3

 

Description of Additional Services

 

[Intentionally Omitted]Exhibit 10.12.4

 

Certain identified
information has been excluded from the exhibit pursuant to Item 601(b)(10)(iv) because it is both not material and is the type of
information that the registrant treats as private or confidential. Redacted information is indicated by: [***]

 

Amendment #4

 

Consulting Agreement dated October 17, 2016
between

 

ProMIS Neurosciences, Inc. and Danforth
Advisors, LLC

 

This Amendment No. 4
to Consulting Agreement (“Amendment”) is made as of October 1, 2021 (“Effective Date”), by and between ProMIS
Neurosciences, Inc. (“Company”) and Danforth Advisors, LLC (“Consultant” or “Danforth”). Capitalized
terms used but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Danforth Advisors
and the Company dated as of October 17, 2016 (“Agreement”).

 

WHEREAS,
Danforth is engaged by the Company under the terms and conditions of the Consulting Agreement; and

 

WHEREAS,
the Company and Consultant mutually desire to amend the term and scope of the Agreement.

 

NOW,
THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained and for the other good
and valuable consideration, receipt of which is hereby acknowledge, the parties hereby agree as follows:

 

		1.	Section 3. Term and Termination is hereby modified to extend the term of the Agreement until
October 29, 2024.

 

		2.	Exhibit A to the Agreement is hereby modified to allow Danforth to add the services of various Danforth
employees to perform the Services required and approved, such approval to be provided verbally or by email, by the Company at each such
Danforth employee’s billable rate in effect at the time they are added to the Agreement. The billable rates in effect as of the
date of this Amendment No.1 are as described in Exhibit A-4.

 

		3.	Except as specifically provided for in this Amendment, the terms of the Agreement shall be unmodified
and shall remain in full force and effect.

 

This Amendment may be executed in one
or more counterparts, each of which shall be considered an original instrument, but all of which shall be considered one and the same
Amendment, and shall become binding when one or more counterparts have been signed by each of the parties and delivered to the other.

 

     

     

    

 

IN WITNESS WHEREOF, this Amendment
has been executed by the Company and Danforth to be effective as of the date first above written.

 

	DANFORTH ADVISORS, LLC	 	PROMIS NEUROSCIENCES, INC.
	 	 	 
	By: 	/s/ Chris Connors	 	By: 	 
	 	 	 
	Print
    Name:      Chris Connors	 	Print
    Name:      Eugene Williams
	 	 	 
	Title:
      Chief Executive Officer	 	Title:
      Executive Chairman
	 	 	 
	Date: 	11/10/2021	 	Date: 	/s/ Eugene Williams

 

    2

     

    

 

Exhibit A-4

 

Description of Services and Schedule of Fees

 

Danforth will perform mutually agreed to finance
and accounting functions which are necessary to support the management and operations of the Company including, but not limited to, the
functions set forth below:

 

	Role	 	Hourly
    Rate	 	Function
	 	 	 	 	 
	Sr. Advisor	 	$[***]/hour	 	Senior Advisory 
	 	 	 	 	 
	CFO	 	$[***]/hour	 	CFO
	 	 	 	 	 
	Sr. Director	 	$[***]/hour	 	Principal Accounting Officer 
	 	 	 	 	 
	Sr. HR Director	 	$[***]/hour	 	Human Resources 
	 	 	 	 	 
	HR Director	 	$[***]/hour	 	Human Resources
	 	 	 	 	 
	Director	 	$[***]/hour	 	VP Finance
	 	 	 	 	 
	Sr HR Manager	 	$[***]/hour	 	Human Resources 
	 	 	 	 	 
	Sr Manager	 	$[***]/hour	 	Sr Controller/FP&A
	 	 	 	 	 
	Manager	 	$[***]/hour	 	Controller 
	 	 	 	 	 
	HR Manager	 	$[***]/hour	 	Human Resources 
	 	 	 	 	 
	Sr. Consultant	 	$[***]/hour	 	Asst. Controller 
	 	 	 	 	 
	Consultant	 	$[***]/hour	 	Staff Accountant

 

Mr. Daniel
Geffken will work for a monthly fixed fee of $15,000 (estimated at a 35 hour commitment /month), commencing October 1, 2021. As additional
consideration for the fixed fee arrangement, the Board of Directors of the Company will vote at its next Board Meeting on November 11,
2021 to provide Danforth an option (the “Danforth Option”) to purchase 500,000 shares of common stock. The Danforth Option
shall have a 10-year term an exercise price equal to the fair value of the common stock as determined by the Board of Directors of the
Company on the date such option is issued and shall vest ratably over 12 months commencing on the Effective Date, subject to the continued
provision of services to the Company by Danforth as of each vesting date. If this agreement is terminated by the Company within 6 months
of the Effective Date, for other than cause, then shares as to 50% of the Danforth Option shall vest. The Company and Danforth will enter
into a separate stock option agreement within 30 days of the Effective Date, to be negotiated in good faith.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]